Biomarker Research

Papers
(The H4-Index of Biomarker Research is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma144
Gene therapy for polygenic or complex diseases125
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases116
Molecular mechanisms and clinical applications of exosomes in prostate cancer98
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia97
Extrachromosomal circular DNA (eccDNA): an emerging star in cancer94
The solute carrier transporters (SLCs) family in nutrient metabolism and ferroptosis87
Minimal residual disease in multiple myeloma: current status78
Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma74
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics74
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients70
FGL1 and FGL2: emerging regulators of liver health and disease69
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma66
SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma65
Novel strategies for immuno-oncology breakthroughs with cell therapy62
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model61
Radiogenomic association of deep MR imaging features with genomic profiles and clinical characteristics in breast cancer60
New insights into the function of Interleukin-25 in disease pathogenesis56
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives55
Proteomics to predict relapse in patients with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation55
MicroRNAs predict early complications of autologous hematopoietic stem cell transplantation50
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma49
Circulating extracellular vesicles during pregnancy in women with type 1 diabetes: a secondary analysis of the CONCEPTT trial48
Effects of protein restriction on insulin-like growth factor (IGF)-1 in men with prostate cancer: results from a randomized clinical trial46
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer46
Correction: Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis45
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis44
Metastasis-associated fibroblasts: an emerging target for metastatic cancer42
Decoding burn trauma: biomarkers for early diagnosis of burn-induced pathologies42
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma41
Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies40
Tumor reversion: a dream or a reality39
A metabolite-based liquid biopsy for detection of ovarian cancer39
New cell sources for CAR-based immunotherapy38
METTL protein family: focusing on the occurrence, progression and treatment of cancer36
Sintilimab for the treatment of non-small cell lung cancer36
Risk factors for immune-related adverse events: what have we learned and what lies ahead?36
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors36
0.12506580352783